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ABSTRACT 
	  
 Hypertension is a major risk factor for heart disease and stroke, which are the 
leading causes of death worldwide. Anti-hypertensive drugs account for the major drug class 
used in the treatment and prevention of cardiovascular diseases, although their use is based 
on a trial-and-error rationale. For anti-hypertensive drugs the percentage of non-responders 
can reach 20% of the patients under treatment, and non-compliance due to adverse drug 
responses is frequent.  
 Among the causes known which account for differences in drug response are the 
interindividual genetic differences - the focus of study in Pharmacogenomics. Being able to 
provide Pharmacogenomic tests in a community pharmacy setting gives the pharmacist an 
opportunity to individualize drug therapy, maximising efficacy and minimising toxicity, based 
on patients’ genetic data. 
 Given the number of hypertensive patients (circa 30% of global population), the 
expenditure with cardiovascular drugs (one million euros per day in reimbursements in 
Portugal) and the difficulty in finding the right drug for each patient, being able to offer 
Pharmacogenomic tests to hypertensive patients in a community pharmacy setting is an 
opportunity that should be seized. 
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1. Introduction 
 
Hypertension, or high blood pressure, is a major risk factor for heart disease and 
stroke, which are the leading causes of death worldwide (1). According to the World Health 
Organization (WHO), as depicted in Figure 1, it is only in the low income countries that 
heart disease does not account for the major cause of death. 
 
 
Figure 1- Top ten causes of death across the world 
(Adapted from the World Health Organization Fact Sheets, accessed in September 2012) 
 
In a scientific study published in 2005(2), it was shown that in the year 2000, 26.4% of 
the adult population had hypertension (26.6% of men and 26.1% of women), and 29.2% were 
projected to have this condition by 2025. The estimated total number of adults with 
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hypertension in 2000 was 972 million; 333 million in economically developed countries and 
639 million in economically developing countries. The number of adults with hypertension in 
2025 was predicted to increase by about 60% to a total of 1.56 billion.  
 
In the World Health Statistics 2012(3) report published by the WHO, it was reported that 
in 2008, in Portugal, under the known causes for mortality between 30 and 70 years old per 
100.000 inhabitants,  the deaths caused by cardiovascular diseases (CVD) and diabetes 
accounted for 23% of all causes of death. In the European region this number rises up to 38% 
of all causes of death. World-wide the percentage of deaths caused by CVD and diabetes is 
32%. 
According to the same report, the prevalence of raised blood pressure among adults 
aged above 25 years old, in 2008, in Portugal, was of 34,5% and 24,3% of the male and female 
population, respectively. Globally, these number accounted for 29,2% of the male population 
and 24,8% of the female population. 
 
 
Figure 2- Prevalence of raised blood pressure among adults age 25+, both sexes, 2008. (Adapted from the World Health 
Organization – Map Gallery) 
 
What was predicted, in 2005, to happen in 2025 (29,2% of hypertensive population) has 
been reached in a far shorter time.  
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Awareness, prevention, treatment and control of hypertension are significant public 
health measures and cost-effective interventions. Nevertheless, and despite the existing 
theoretically knowledge necessary to prevent and control hypertension, control rates are 
dim in every part of the world.  
Many hypotheses have been laid to respond to this fact, one of which is the vast array 
of risk factors for hypertension that include dietary habits, high alcohol consumption, low 
levels of physical activity and overweight. As these are modifiable risk factors, the primary 
treatment includes lifestyle changes. When lifestyle modifications fail to control hypertension, 
pharmacotherapy is essential. Nevertheless, 15% to 20% of all patients fail to respond to drug 
treatment, even with a two-drug combination (4). 
In addition, the responses to anti-hypertensive drugs differ significantly between 
patients, as they depend on several factors such as gender, lifestyle, age, race, disease severity, 
disease progression, underlying illnesses, concomitant pharmacotherapy, patient's compliance 
and individual genetic makeup. 
 Optimal blood pressure control requires increased understanding of the evaluation 
and management of blood pressure, and it is important to be aware that the individual 
genetic variability plays an important role in the differences in drug response. 
 
These individual genetic differences - deoxyribonucleic acid (DNA) polymorphisms - 
are studied under the emerging science of Pharmacogenomics (PGx), which has as its 
ultimate goal to identify the underlying genetic factors that play a role in the efficacy and 
toxicity of all drugs(5).  
Moreover, PGx research refers to the use of appropriate DNA methodologies to 
develop reliable biomarkers to predict drug response, adverse drug responses (ADRs), dose 
requirements, disease susceptibility and stage. It is applicable to activities such as clinical 
practice, drug development and drug discovery. 
 
DNA polymorphisms have been gaining key importance in explaining the outcome of 
drug treatment, as they help explain the differences in the pharmacodynamics and 
pharmacokinetics of drugs in different patients. 
The development of new anti-hypertensive drugs and the survey of the existing ones 
should take into account these polymorphisms in order to adapt the drug and the drug dose 
to each individual and to avoid drug side effects. 
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In 2006, in Portugal, the estimated hypertensive population was of about 2 million 
people. Of these, only half knew they were hypertensive, a quarter was under 
pharmacotherapy and only 16% of this latter population was normotensive (6). These numbers 
clearly show the magnitude of the problem, and because there is a considerable percentage 
of patients that are resistant, even to multi-drug therapy, it is believed to be important to 
study the contribution of individual polymorphisms to the failure of response to drug 
treatment. 
 
Nevertheless, pharmacogenomics is not only useful in understanding drug response 
after pharmacotherapy has been initiated, it has become growingly important in  drug 
development, enabling Stratified Medicine (pro-actively testing and selecting subsets of 
population for treatment based on a likely positive or negative therapeutic response). 
Stratification is driving a trend away from the development of “blockbuster” drugs to that of 
“nichebusters”, which can alter the nature of competition in the pharmaceutical industry.  
This can ultimately lead to Individualised Drug Therapy (IDT), also regarded as 
Personalized Medicine (PM), in which, genotype-based, individually targeted prescribing ought 
to be more effective at improving response rates and decreasing the burdens of adverse drug 
responses (ADRs) (7).  
 
 
Figure 3 - Pharmacogenomic approach to Individualised Drug Therapy. Drug therapy is chosen for each patient based on 
their particular genetic profile.  (Adapted from The Art and Science of Personalized Medicine) 
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In the case of anti-hypertensive drugs, the different classes of drugs act in different 
pathways or in different steps of a physio-pathologic pathway, depending on which receptor 
they bind to, the enzyme they inhibit, or which metabolizing step they affect.  The fact that 
different drugs are being dealt with, amplifies the variability in response. 
 The guidelines proposed by the European Society of Hypertension (ESH), in its 2011 
reappraisal, and the United States Joint National Committee on Prevention, Detection, 
Evaluation, and Treatment of High Blood Pressure (2003) do not recommend the use of one 
drug over another, unless other diseases are present, such as diabetes or renal disease, once 
it has been shown that they do not differ significantly in their overall ability to reduce blood 
pressure in hypertension. 
 Also, because the percentage of patients responsive to any drug class is limited and 
patients responsive to one drug are often not those responsive to another drug, keeping the 
drug options large increases the chance of blood pressure control in a larger fraction of 
hypertensive patients. This is crucial because cardiovascular protection by anti-hypertensive 
treatment substantially depends on lowering blood pressure per se, regardless of how it is 
obtained (4). 
 
 However, not being able to control blood pressure with monotherapy leads to lower 
patient compliance and raises the likelihood of developing an ADR. Among other reasons, this 
could be avoided, as well as the side effects that lead to changing or dropping medication, if 
there were accurate and affordable genetic tests to overcome this problem. Thus, finding the 
right drug(s) to a specific individual would not be based on “trial-and-error” but on clear 
guidelines and algorithms of clinical care. 
 
The available data from pharmacogenomic studies suggests that there are genetic 
polymorphisms that can to be taken into account when prescribing anti-hypertensive drugs. 
An example is the cytochrome P450 enzyme family (CYP), which has a marked influence in 
the pharmacokinetic (PK) phase of drug metabolism, being the genetic polymorphisms of 
CYP2D6 and CYP3A that play an important role in drug response for anti-hypertensive 
drugs. As for the pharmacodynamic (PD) phase of the cardiovascular drugs, polymorphisms in 
the genes encoding for α-Adducin, Angiotensin-Converting-Enzyme (ACE), Angiotensinogen 
and Bradykinin receptor B2 are the most important(7). 
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Pharmacogenomics is redefining how diseases are being diagnosed, classified and 
treated. Pharmacogenomics represent an innovative area for product differentiation, 
competitive advantage and research productivity enhancement. Genetic markers play a major 
role, in spite of the challenges of identifying valid associations and their biological complexity.  
 
However, there are many barriers yet to overcome, such as scientific, economic, 
educational, legal and commercial barriers, before full potential of pharmacogenomics is 
achieved. Nevertheless, the scientific and technological advances in genetics and molecular 
science are escalating, and so does enthusiasm for the potential use of these innovations, 
which can significantly improve medical care delivery and health outcomes. These 
developments, combined with a rich array of new data and analytic tools that are easier, 
faster and cheaper to use, together with improved communication vehicles for health 
engagement, can be used to design targeted care for each individual. 
 
 Pharmacists, in all fields of action, have now another challenge to their careers: 
incorporating the pharmacogenomics principles into their daily practice and making use of its 
tools to better deliver pharmaceutical care, to develop drugs more efficiently or to discover 
drugs with increased safety and efficiency. 
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2. Hypertension 
 
2.1 Definition and Classification of Hypertension 
 
Hypertension, or high arterial blood pressure, is a progressive cardiovascular disease, 
characterized by values of systolic blood pressure over 140mmHg and/or diastolic blood 
pressure over 90mmHg (1). It is the most prevalent cardiovascular disorder in developed 
countries and affects circa 30% of the adult population (2). 
 Progression of the disease is strongly associated with functional and structural cardiac 
and vascular abnormalities that damage the heart, kidneys, brain, vasculature, and other 
organs, which in turn leads to premature morbidity and death. 
 
 Hypertension is classified into different categories according to the blood pressure 
levels. In the 2007 “Guidelines for the Management of Arterial Hypertension” set by the European 
Society of Hypertension and the European Society of Cardiology (ESH/ESC), hypertension is 
classified as follows: 
 
Table 1 - Hypertension Classification  
(acording to the ESH/ESC the classification is based on systolic and diastolic blood pressure) 
Category 
Systolic blood  
pressure (mmHg) 
Diastolic blood 
 pressure(mmHg) 
Optimal < 120 and <80 
Normal 120-129 and/or 80-84 
High Normal 130-139 and/or 85-90 
Grade 1 Hypertension 140-159 and/or 90-99 
Grade 2 Hypertension 160-179 and/or 100-109 
Grade 3 Hypertension ≥ 180 and/or ≥110 
Isolated Systolic Hypertension ≥ 140 and <90 
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The ESH/ESC guidelines also state that: 
 a) when a patient's systolic and diastolic blood pressure fall into different categories, 
the higher category should apply for the quantification of total cardiovascular risk, decision 
about drug treatment and estimation of treatment efficacy; 
 b) isolated systolic hypertension should be graded (grades 1, 2 and 3) according to 
the same systolic blood pressure values indicated for systolic-diastolic hypertension. 
However, the association with a low diastolic blood pressure should be regarded as an 
additional risk; 
 c) the threshold for hypertension (and the need for drug treatment) should be 
considered as flexible based on the level and profile of total cardiovascular risk. (3) 
 
2.2 Cardiovascular Risk Assessment 
 
Cardiovascular risk factors include hypertension and high total cholesterol, high levels 
of triglycerides, high levels of low-density lipoprotein or low levels of high-density lipoprotein 
(HDL) cholesterol.  
Smoking also increases risks of cardiovascular disease.  The risk is especially high for 
early smokers, for those who smoke heavily or for women. Stopping tobacco use can reduce 
the risk of cardiovascular disease significantly, despite how long a person has been smoking.  
Physical inactivity increases the risk of heart disease and stroke by 50%.  Obesity is a 
major risk for cardiovascular disease and predisposes to diabetes. Diabetes is a risk factor for 
cardiovascular disease.  
Type 2 diabetes is a major risk factor for coronary heart disease and stroke. Having 
diabetes rises twofold the likelihood to develop cardiovascular disease.  
Left ventricular hypertrophy is a risk factor for cardiovascular mortality.  
Risk of stroke doubles every decade after age 55. If a first-degree blood relative has had 
coronary heart disease or stroke before the age of 55 years, for a male relative or 65 years, 
for a female relative, the risk increases. 
 The gender is significant: a male is at greater risk of heart disease than a pre-
menopausal woman.  But once past the menopause, a woman’s risk is similar to a man’s. Risk 
of stroke is similar for men and women.  
The ethnic origin also plays a role.  People with African or Asian ancestry are at higher 
risks of developing cardiovascular disease than other racial group. 
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Cardiovascular risk can, then, be stratified as follows (Table 2):  
 
Table 2 - Cardiovascular risk stratification chart. Low, moderate, high and very high risk refers to the 10-year risk of 
a CV fatal or non-fatal event. The term 'added' indicates in all categories that risk is greater than average. The risk factors 
referred to in the left column are: age, smoking, dyslipidaemia, elevated fasting plasma glucose, abnormal glucose tolerance 
test, abdominal obesity, a family history of premature CVD and 'high pulse pressure in the elderly'.  (Adapted from the 2007 
Guidelines for Management of Arterial Hypertension (ESH/ESC)). 
Risk factors 
Blood Pressure (Category) 
Normal High Normal Grade 1 HT Grade 2 HT Grade 3 HT 
No other risk factor Average risk Average risk 
Low added  
risk 
Moderate added 
risk 
High added risk 
1-2 risk factors 
Low added  
risk 
Low added  
risk 
Moderate added 
risk 
Moderate added 
risk 
Very high added 
risk 
3 or more risk factors 
Moderate added 
risk 
High added 
 risk 
High added risk High added risk 
Very high added 
risk 
Established CVD or renal 
disease 
Very high added 
risk 
Very high added 
risk 
Very high added 
risk 
Very high added 
risk 
Very high added 
risk 
 
 This chart, among other tools, such as the Framingham Risk Score (4), helps to predict 
the risk of an individual having a CV event in the next 10 years. It is a powerful tool, available 
to every healthcare professional, but it does not convey the genetic information for individual 
DNA polymorphisms that can help decide the treatment. 
 
2.3 Physiological Control of Blood Pressure 
 
The human body has many mechanisms to control blood pressure: by changing the 
amount of blood the heart pumps, by changing the diameter of the vessels or by changing the 
volume of blood in the bloodstream. 
 To increase blood pressure the heart can pump more blood either by pumping more 
forcefully or more rapidly, arterioles can constrict, forcing the blood from each heartbeat 
through a narrower space than normal and fluid can be added to the blood stream to 
increase blood volume. Conversely, to decrease blood pressure, the heart can pump less 
forcefully or rapidly, arterioles and veins can dilate and fluid can be removed from the 
bloodstream. 
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These mechanisms are controlled by the sympathetic division of the autonomic 
nervous system (involuntary) and by the kidneys.  
 The sympathetic nervous system stimulates the adrenal gland to release the 
hormones epinephrine (adrenaline) and norepinephrine (noradrenaline). Both hormones 
raise blood pressure by causing peripheral vasoconstriction and increase cardiac output (5). 
 The kidneys also respond directly to changes in blood pressure. If blood pressure 
increases, the kidneys increase their excretion of salt and water, so the blood volume 
decreases and blood pressure returns to normal. On the other hand, if blood pressure falls, 
the kidneys decrease their excretion of salt and water so blood volume increases and blood 
pressure returns to normal. 
Also, kidneys can raise the blood pressure by secreting an enzyme, renin, which triggers 
the Renin-Angiotensin-Aldosterone System (RAAS). In Figure 4 a schematic drawing of 
the RAAS is shown, where inhibitory and stimulatory pathways are depicted.  
 
  
 
Figure 4 - Renin-Angiotensin-Aldosterone System.  Blue and red dashed arrows indicate stimulatory or inhibitory 
signals, which is also indicated by the +/-. In the tubule and collecting duct graphics, the grey dashed arrows indicate passive 
transport processes, contrary to the active transport processes which are indicated by the solid grey arrows. The other 
solid arrows either indicate a secretion from an organ (blue, with a starting Spot) or a reaction (black). These two processes 
can be stimulated or inhibited by other factors.  (Adapted from Wikipedia). 
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 The RAAS plays an essential role in the homeostatic control of the arterial blood 
pressure, tissue perfusion and extracellular volume. 
 The pathway is initiated by the secretion of renin, the rate-limiting processing enzyme, 
from the kidney by an exocytic process involving stimulus-secretion coupling into the renal 
and then the systemic circulation. Renin secretion is stimulated by a fall in perfusion pressure 
or in NaCl delivery and by an increase in sympathetic activity. 
  
Control of renin secretion is a key determinant of the activity of RAAS. Renin regulates 
the initial, rate-limiting step of the RAAS by cleaving angiotensinogen to form the biologically 
inert angiotensin I. The primary source of systemic circulating angiotensinogen is the liver. It's 
secreted constitutively by the liver, so plasma levels are generally stable. The inactive 
angiotensin I is hydrolysed by Angiotensin-Converting-Enzyme (ACE), to form a biological 
active and potent vasoconstrictor molecule: angiotensin II. ACE is a membrane-bound 
exopeptidase and is located on the plasma membranes of various cell types and though it 
also exists in a soluble form in plasma, it is the membrane-bound ACE that is thought to be 
physiologically important. ACE metabolizes a number of other peptides, including vasodilator 
peptides bradykinin and kallidin, to inactive metabolites. Thus, functionally, the enzymatic 
actions of ACE potentially result in increased vasoconstriction and decreased vasodilation. 
Angiotensin II is the primary effector of a variety of RAAS-induced physiological and 
pathophysiological actions. At least four angiotensin (AT) receptors have been described: 
 AT1 mediates most of the established physiological and pathophysiological effects of 
angiotensin II. These include actions on the cardiovascular system (vasoconstriction, 
increased blood pressure, increased cardiac contractility, vascular and cardiac 
hypertrophy), kidney (renal tubular sodium reabsorption, inhibition of renin release), 
sympathetic nervous system and adrenal cortex (stimulation of aldosterone 
synthesis). It also mediates effects of angiotensin II on cell growth and proliferation, 
inflammatory responses and oxidative stress; 
 AT2 receptor levels decrease markedly in the postnatal period but there is evidence 
that it might mediate vasodilatation and antiproliferative and apoptotic effects in 
vascular smooth muscle and inhibit growth and remodelling in heart; 
 AT3 receptor's function is unknown; 
 AT4 receptors are thought to modulate the endothelial function.  
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As stated before, angiotensin II, via AT1 receptor also stimulates the production of 
aldosterone. Aldosterone is a major regulator of sodium and potassium balance and thus 
plays a major role in regulating extracellular volume. It enhances the reabsorption of sodium 
and water in the kidney's distal tubules and collecting ducts and thereby promotes potassium 
and ion hydrogen excretion. 
 
Deregulation of the RAAS is involved in the pathogenesis of several hypertensive 
disorders. In addition to the RAAS involvement in secondary forms of hypertension, there is 
evidence that perturbations of the RAAS are involved in essential hypertension (6). 
 
2.4 Causes for Hypertension 
 
Hypertension is divided into two types: primary or essential hypertension and 
secondary hypertension.   
 Primary hypertension has no identifiable cause, it is the type of hypertension with 
more predominance in adults and tends to develop gradually over the years.  
 On the other hand, some people have high blood pressure caused by an underlying 
condition. This type of high blood pressure, called secondary hypertension, tends to 
appear suddenly and causes higher blood pressure than does primary hypertension. Various 
conditions and medications can lead to secondary hypertension, including: kidney problems, 
adrenal gland tumours, congenital diseases, certain drugs, such as birth control pills, cold 
remedies, decongestants, over-the-counter pain relievers and some prescription drugs. 
 
2.5 Pharmacological Treatment of Hypertension 
 
Because renin is the initial and rate-limiting step in RAAS cascade, it has long been 
considered the logical therapeutic target for blocking the system. However, pharmacological 
activity of the early renin inhibitors could only be achieved with intravenous infusion, and the 
development of an orally active direct renin inhibitor was fraught with numerous difficulties 
arising from issues of potency, low bioavailability, duration of action and costs of synthesis. 
Since then, these obstacles have been overpassed and the renin inhibitor aliskiren is the 
newest anti-hypertensive molecule in the market. 
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 Anti-hypertensive drugs are classified in several classes: 
a) Beta-blockers (β-blockers); 
b) Angiotensin-Converting Enzyme Inhibitors (ACEI); 
c) Angiotensin II Receptor Blockers (ARB); 
d) Direct Renin Inhibitors; 
(all of the above act in the RAAS system.) 
e) Diuretics; 
f) Calcium Channel Blockers. 
 
In the following Table 3, are depicted some examples of drugs that belong to the 
different classes presented before: 
 
Table 3 - Examples of antihypertensive drugs, their mechanism of action and diseases in which they are used. 
 
 
Antihypertensive drugs 
Acting in RAAS 
Diuretics 
Calcium 
Channel 
Blockers 
Β-blockers ACEI ARB 
Direct Renin 
Inhibitors 
Drugs 
(e.g.) 
Atenolol 
Propranolol 
Bisoprolol 
Captopril 
Enalapril 
Lisinipril 
Ramipril 
Candesartan 
Irbesartan 
Losartan 
Valsartan 
Aliskiren 
Hydrochlotiazide 
Indapamide 
Furosemide 
Amiloride 
Diltiazem 
Verapamil 
Amlodipine 
Nifedipine 
Mechanis
m 
of action 
Reduces 
plasma renin 
levels by 
blocking 
sympatheticall
y β-1 
mediated 
renin release 
by the kidney 
ACEIs competitively 
block the action of 
ACE and thus the 
conversion of Ang I to 
Ang II, thereby 
reducing circulating 
and local levels of Ang 
II 
Specific 
antagonism of 
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It is stated, in the 2007 Guidelines for the Management of Arterial Hypertension of the Task 
Force for the Management of Arterial Hypertension (6), edited by the ESH, that “for treatment 
initiation, it is recommended that for Grade 1 hypertensive patients (Systolic Blood Pressure 
(SBP) ≥ 140mmHg or Diastolic Blood Pressure (DBP)  90 mmHg), at low and moderate 
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risk, drug therapy should be started after a suitable time period with life changes. Prompter 
initiation of treatment is advisable if Grade 1 hypertension is associated with high level of 
risk, or if hypertension is Grade 2 or 3.  In general, early blood pressure lowering treatment, 
before organ damage develops or becomes irreversible or cardiovascular events occur, 
appears a prudent recommendation, because in high risk hypertensive patients, even intense 
cardiovascular drug therapy, though beneficial, is nonetheless unable to lower total CV risk 
below the high risk threshold. On the whole, there is sufficient evidence that SBP be lowered 
below 140mmHg (and DBP below 90mmHg) in all hypertensive patients, both those at low 
moderate risk and those at high risk.”  
As for the choice of antihypertensive drugs, “the main benefits of antihypertensive 
treatment are due to lowering of BP per se, and are largely independent of the drugs 
employed. Therefore, thiazide diuretics (as well as chlorthalidone and indapamide), beta-
blockers, calcium antagonists, ACE inhibitors and ARB can adequately lower blood pressure 
and significantly and importantly reduce CV outcomes. All these drugs are suitable for the 
initiation and maintenance of antihypertensive treatment either as monotherapy or in some 
combinations with each other. Because the percentage of patients responsive to any drug 
class is limited and patients responsive to one drug are often those not responsive to 
another drug, keeping the number of drug options large increases the chance of blood 
pressure control in a larger fraction of anti-hypertensive patients. This is of crucial 
importance because cardiovascular protection by antihypertensive treatment substantially 
depends on blood pressure lowering per se, regardless of how it is obtained.” 
 
Nevertheless, resistant hypertension is not a phenomenon of marginal proportions, the 
number of patients unable to achieve blood pressure control despite multiple drug treatment 
being around 15-20% (7). No matter which drug is employed, monotherapy can effectively 
reduce blood pressure in only a limited number of hypertensive patients, most of whom 
require the combination of at least two drugs to achieve blood pressure control. Combining 
two agents from any two classes of antihypertensive drugs increases the blood pressure 
reduction much more than doubling the dose of one agent. 
 
Although it is possible that the use of two drugs together implies the administration of 
a futile one, searching for the most effective monotherapy in every given patient is 
painstaking and may discourage compliance.  
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The avoidance of ADRs is also a matter of interest for pharmacogenomics. About 35% 
of hypertensive patients discontinue their medication within six months, 50% of which due to 
adverse effects and patient dissatisfaction (8). One of the most common ADR is hypotension. 
This may be caused by overdose or overtreatment, but genomics can also be the answer if 
onset of action is too quick or metabolism is more extent. Hypotension is felt through 
symptoms such as dizziness, fatigue and anxiety. These are reasons enough to quit treatment, 
especially if these symptoms interfere with normal daily activities. Angiotensin-Converting-
Enzyme Inhibitors can cause dry cough, which is difficult to overcome, even with drug 
treatment, and can disturb sleep or speech. Headaches, palpitation, flushing, alopecia and 
constipation are some adverse effects felt with treatment with calcium channel blockers. 
Beta-blockers may cause sleep disturbances, erectile dysfunction and glucose intolerance 
(important in diabetic patients). 
These are the most perceived ADRs, others such as angioedema, renal dysfunction, 
hypokalaemia, hyponatremia or gout may only be diagnosed in advanced stages and, in some 
cases, be life-threatening. 
 
For antihypertensive treatment, not only the costs of therapeutics are at stake, but also 
the costs of non-compliance and of ADRs. 
 In 2010, high blood pressure was projected to cost the United States $93.5 billion in 
health care services, medications, and missed days of work. These costs are projected to 
increase in the following twenty years, as can be seen in Figure 5 (9). 
 
Whether it is by being able to choose the best drug treatment or in predicting which 
adverse effects will be present in a particular individual, pharmacogenomics can play a major 
role in defining therapeutic strategies for hypertension, cutting down health expense, 
improving adherence and optimizing drug therapy.  
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Figure 5- Projected direct and indirect costs of all CVD, 2010 to 2030 (in billions 2008$).  (Adapted from Forecasting the 
Future of Cardiovascular Disease in the United States )(9). 
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3. Pharmacogenomics 
 
In April 2003 the complete sequencing of the human genome was released by the 
Human Genome Project. It coincided with the 50th anniversary of the research publication 
announcing the discovery of the DNA's double helix.  
 
 
Although both achievements have been hallmarks of science, in the last decade genetic 
research has advanced from the human genome sequencing to the mapping of genetic 
variations among individuals. Recently, these individual genetic variations have been associated 
with and used to identify diseases and predict drug response and adverse reaction.  
 
Figure 6 - James Watson (1928-) and Francis Crick (1916-2004) original paper (left). Both scientists showing a 3D model 
of their proposed DNA structure (right). 
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Each individual has a particular drug response, ranging from high efficacy and no toxicity 
to no efficacy and high toxicity. This drug response depends on several factors, such as: 
gender, lifestyle, age, race, disease severity, disease progression, underlying illnesses, 
concomitant drug therapy and the genetic makeup. 
 
For the last century there has been increasing evidence that how individuals respond to 
drugs varies, to some extent, according to inherited characteristics and are therefore genetic 
bound. These inter-individual genetic variations that result in different drug responses are 
studied in a fairly new and fast growing field of science: pharmacogenomics. 
 
3.1 History of Pharmacogenomics 
 
It has been almost 150 years since the publication of Gregor Mendel's “Versuche über 
Planzenhybriden” (Experiments in plant hybridization, 1865), the hallmark of genetics. In this 
brilliant paper, Mendel brought forward the principles of heredity, introduced us to the 
meaning of dominant and recessive characteristics and was the first to apply mathematics and 
statistics to a biological problem (1). 
 
 Six years before Charles Darwin had published “On the Origins of Species” (1859) 
and four years later DNA was isolated (Miesher, 1869).  
In 1902, Archibal E. Garrod published in “The Lancet” a paper where he found that 
“there are good reasons for thinking that alkaptonuria is not the manifestation of a disease, is 
rather of the nature of an alternative course of metabolism, harmless and usually congenital 
and lifelong.” (2). This is considered to be the first pharmacogenetics paper ever written, 
though the term “pharmacogenetics” would only make its appearance in 1959, through 
Vogel's work (“Modern Problem der Humangenetic”) in which he described this new 
scientific discipline that dealt with inherited differences in response to drugs. 
In 1962, Kalow W. published the first book in the field: “Pharmacogenetics: Heredity and 
the response to drugs”.  
Through the years, along with the unveiling of the complete human genome sequence, 
genetic testing has evolved from the study of rare monogenic diseases to more common and 
genetically complex diseases such as cancer or cardiovascular disorders. Nowadays 
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pharmacogenomic testing has been the focus of many scientist's work, who try to find the 
answer to how DNA polymorphisms can be related to drug response. 
 
3.2 Definitions  
 
The genome of an organism comprises the entire DNA that can be found in a cell 
(nuclear and mitochondrial). Within this DNA are genes that function to build and maintain 
the organism, and circa 95% of the genes are transcribed into messenger ribonucleic acid 
(mRNA) which ultimately are translated into proteins.  
 
 
Figure 7- From genes to proteins (Adapted from http://www.scq.ubc.ca/the-human-genome-project-the-impact-of-
genome-sequencing-technology-on-human-health/). 
 
 Genomics study the structure of genes (how they are organized and how that 
organization is relevant to gene regulation and function), the content of the genome and the 
evolution of genomes.  The genome size and complexity vary greatly among organism, for 
example, the human genome is made of about 23.000 genes, with 3.000.000 of base pairs, 
while the rat genome has 25,557 genes, with 275.000 of base pairs.  
With so many base pairs (and genes), the human genome is greatly diverse, especially if 
it is taken into account the copying errors that can occur during DNA replication. With each 
generation, the genetic material contained in the chromosomes must be copied. It is during 
this copying process that mutations can occur in the DNA sequence. These changes 
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ultimately give rise to the diversity of life…and of drug response (the object of study of 
PGx). 
 Mutations can encompass changes from a single base pair substitution (single nucleotide 
polymorphisms (SNPs)), to de addition or loss of DNA.  
Aside from approximately 23.000 functioning genes, humans have nearly as much of non-
functioning pseudogenes. Of the functioning genes, 5 to 10% are RNA genes. The remaining genes are 
transcribed into mRNA and translated into proteins. 
 
Gene’s nomenclature is also important to understand. Gene names are determined by the 
Human Genome Organization that approves an unique name and symbol for each gene, so it can be 
clearly perceived by all. Gene names are generally short and intended to convey some information as 
to their function. Members of the same gene superfamily share the same root name (e.g., cytochrome 
P450 superfamily gene all start with CYP), and Arabic numerals are used to distinguish individual 
members of the family (examples in Table 4). Given that in humans the rate of mutations is 
approximately 2,5 changes in 108 sites per generation, per gene, there are many variants. These 
variants (or alleles), are designated by the gene name followed by an asterisk and an Arabic numeral, 
for example: CYP3A4*2 is one allele of at least 20 known alleles in this gene (3). 
 
Table 4 - Gene nomenclature (examples).   
Approved Symbol Approved Name 
Chromosome 
location 
CYP1A1 cytochrome P450, family 1, subfamily A, polypeptide 1 15q24.1 
CYP2A6 Cytochrome P450, family 2, subfamily A, polypeptide 6 19q13.2 
VKORC1 Vitamin K epoxide reductase complex, subunit 1 16p11.2 
NAT6 N-acetyltransferase 6 (GCN5-related) 3p21.3 
UGT1A7 UDP glucuronosyltransferase 1 family, polypeptide A7 2q37 
  
Pharmacogenetics and pharmacogenomics are two complementary principles. 
As defined by the WHO: “Pharmacogenomics refers to the study of DNA sequence variation 
as it relates to differential drug response in individuals, i.e., the use of genomics to determine 
an individual's response. Pharmacogenetics refers to the use of DNA-based genotyping, in 
order to target pharmaceutical agents to specific patient populations in the design of drugs” 
(WHO Drug Information, Vol 16, No.1, 2002). But, both terms can be used interchangeably (3) 
and the term pharmacogenomics will be used hereafter.  
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Pharmacogenomics research encompasses the use of appropriate DNA methodologies 
to develop reliable biomarkers to predict drug response, ADRs, dose requirements, disease 
susceptibility and stage. It is applicable to activities such as clinical practice, drug development 
and drug discovery. 
 
 After administration, the drug response depends on its disposition (pharmacokinetics, 
PK) and effect (pharmacodynamics, PD).  
  
Pharmacokinetic effects are due to inter-individual differences in absorption, 
distribution, metabolism, or excretion (ADME) of the drug. Inappropriate concentration of 
the drug, existence of inappropriate metabolites or both can result in a lack of efficacy or in 
toxicity. Such PK effects are linked mainly to the cytochrome P450 enzyme family, but also to 
membrane transporters or other metabolizing enzymes. 
Variations in ADME genes can result in the absence of a protein or the production of a 
protein with altered or no activity (including transporters, enzymes and drug targets). There 
have been found many variations in genes accounting for the variation in plasma drug 
concentration, such as mutations in the CYP2D6. The clinical significance of these variations 
depends primarily on the contribution of the specific pathway to the overall metabolism of 
the drug, as well as the activity of its metabolites. 
 
Pharmacodynamic effects may lead to inter-individual differences in a drug response, 
albeit the presence of appropriate drug concentrations at the intended site of action. DNA-
based variation in the target molecule's gene or downstream mechanistic pathway genes may 
also explain the variability among subjects in drug response (3) (Figure 8). 
 
Nowadays PGx is not only applied in the study of response to drugs but also as a guide 
to drug development, as the pharmaceutical industry searches for innovation, increased 
productivity, ways to better differentiate from competitors, and ways to bring better, safer, 
more efficient drugs to market with lower costs of development. 
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Figure 8- A schematic overview of genetic variability affecting drug response and disposition. [C] is the drug concentration 
and t is time. (Adapted from Bathenha A, Pharmacogenetics: improving drug and dose selection). 
  
In January 2012, the Committee for Medicinal Products for Human Use (CHMP) 
adopted the Guideline on the use of PGx methodologies in the pharmacokinetic evaluation 
of medicinal products, proposed by the European Medicines Agency (EMA). The aim of this 
guideline is “to clarify the requirements related to the use of pharmacogenetics in the 
pharmacokinetic evaluation of medicinal products”. It “addresses the influence of 
pharmacogenetics on drug pharmacokinetics, encompassing considerations and requirements 
for design and conduct investigations during drug development”. This guideline considers of 
high importance the existence of pharmacogenetics/pharmacogenomics studies where they 
play a key role in establishing the benefit-risk of a drug in the different stages of drug 
development. 
 
In a clinical setting, the application of pharmacogenomics to an individual can be 
referred to as Individualised Drug Therapy (IDT). This ability to offer the right treatment to 
the right person as needed, with pharmacogenomics-based individualized pharmacotherapy is 
its ultimate goal. But not only the genetic makeup must be taken into account, the clinical 
status and the environmental information are also of importance. And being able to translate 
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these findings into precise diagnostic tests and targeted therapies is what scientists, 
physicians and patient are longing for. 
There are many advantages that IDT offers, to both doctors and patients, such as the 
ability to make more informed medical decisions, higher probability of desired outcomes 
given better targeted therapies, reduced probability of negative ADRs, focusing on prevention 
and prediction disease rather than reaction to it, earlier disease intervention and reduced 
healthcare costs (4). 
 
Another term is often used – stratified medicine – which means pro-actively testing 
and selecting subsets of populations for treatment based on a likely positive or negative 
therapeutic response. Stratification is driving a trend away from the development of 
“blockbuster” drugs to that of “nichebuster”, which could ultimately alter the nature of 
competition in the pharmaceutical industry (3). 
 
Also important is the definition of genomic biomarker: “a measurable DNA and/or 
RNA characteristic that is an indicator of normal biologic processes, pathogenic processes, 
and/or response to therapeutic or other interventions.” (6). Many of the pharmacogenomics 
research includes the identification of these biomarkers and then translating this information 
into predictive tests for further use in clinical or drug development settings. 
 
3.3 Genomic Technologies 
  
Technological advances in the past decade, in the field of genomics, such as fast DNA 
sequencers or high-throughput DNA screening, have facilitated rapid biomarker discovery, 
the unravelling of new targets and enabled mechanistic studies that helped to understand the 
drug’s mechanisms of action.   
 
The discovery of the cellular tools necessary to cut and restrict DNA initiated the 
revolution in molecular biology. On this discovery a Nobel Prize was awarded to Werner 
Arber, Dan Nathans and Hamilton Smith, in 1978, for “the discovery of restriction 
enzymes (or endonucleases) and their application to problems of molecular genetics"(6).  
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Figure 9 - Restriction Enzymes. Given the size of the genome, the ability to reliably and repeatedly cut DNA at specific 
locations and recover specific fragments with known sequences at each end, allows scientists to part the genome in sections 
small enough to study.  The restriction enzymes are isolated from bacteria and recognize short sequences of double-strand 
DNA, which they cut leaving behind sticky ends (as in Figure 9) or blunt ends. With the ability to reliably produce DNA 
fragments with known sticky ends, it is possible to recombine fragments by using overlapping ends to facilitate the joining of 
the DNA fragments. Typically, DNA fragments are ligated into specialized plasmids as vectors for the DNA fragment to allow 
further study, replication or sequencing. (Adapted from http://www.tumblr.com/tagged/process?before=1352065342). 
 
 The next important step was to discover a method to determine the sequence of 
DNA.  
In 1977, Frederic Sanger proposed a method to sequence the DNA – Sanger 
Sequencing Method – that is based on the use of dideoxynucleotides (ddNTP’s) in addition 
to the normal nucleotides (NTP’s) found in DNA. Dideoxynucleotides are essentially the 
same as nucleotides except they contain a hydrogen group on the 3’ carbon instead of a 
hydroxyl group (OH). These modified nucleotides, when integrated into a sequence, prevent 
the addition of further nucleotides. .This occurs because a phosphodiester bond cannot form 
between the dideoxynucleotide and the next incoming nucleotide, and thus the DNA chain is 
terminated.  
The Nobel Prize in Chemistry was awarded to him in 1980 in this discovery, to be 
added to a former one, in 1958, for his work on the structure of proteins, especially that of 
insulin.  
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Figure 10 –Sanger Sequencing Method -The classical chain-termination method requires a single-stranded DNA 
template, a DNA primer, a DNA polymerase, normal deoxynucleotidetriphosphates (dNTPs), and modified nucleotides 
(dideoxyNTPs) that terminate DNA strand elongation. These chain-terminating nucleotides lack a 3'-OH group required 
for the formation of a phosphodiester bond between two nucleotides, causing DNA polymerase to cease extension of 
DNA when a ddNTP is incorporated. The ddNTPs may be radioactively or fluorescently labeled for detection in automated 
sequencing machines. The DNA sample is divided into four separate sequencing reactions, containing all four of the 
standard deoxynucleotides (dATP, dGTP, dCTP and dTTP) and the DNA polymerase. To each reaction is added only one 
of the four dideoxynucleotides (ddATP, ddGTP, ddCTP, or ddTTP). Following rounds of template DNA extension from the 
bound primer, the resulting DNA fragments are heat denatured and separated by size using gel electrophoresis. This is 
frequently performed using a denaturing polyacrylamide-urea gel with each of the four reactions run in one of four 
individual lanes (lanes A, T, G, C). The DNA bands may then be visualized by autoradiography or UV light and the DNA 
sequence can be directly read off the X-ray film or gel image. Technical variations of chain-termination sequencing include 
tagging with nucleotides containing radioactive phosphorus for radiolabelling, or using a primer labeled at the 5' end with 
a fluorescent dye. (Adapted from http://www.nature.com/nbt/journal/v26/n10/fig_tab/nbt1486_F1.html). 
  
 In the 1980’s another advance in molecular biology made it possible to amplify a 
specific DNA fragment by a billion-fold within a heterogeneous mix of DNA: Polymerase 
Chain Reaction (PCR). Again this discovery led to a Nobel Prize in Chemistry awarded to 
Michael Smith, in 1993. 
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Figure 11 - Polymerase Chain Reaction: it employs short, specific primers that anneal to the opposing strands of 
denatured double-strand DNA and a DNA polymerase to synthesize new complementary strands. This cycle can be 
repeated several times. The primers are designed to be complementary and specific to the region which is to be amplified. 
(Adapted from http://www.nature.com/scitable/content/using-polymerase-chain-reaction-to-amplify-even-19492). 
 
 These three tools, restriction enzymes, Sanger sequencing and PCR, were the ground 
pillars for the development of many genomic technologies that are used nowadays: next-
generation sequencing (NGS) systems, DNA microarrays and Real-Time PCR. 
 
 The NGS comprise the massively parallel DNA sequencing that can generate in a 
single experiment a great amount of sequenced DNA. These technologies use miniaturized 
and parallelized platforms for sequencing of 1–100 million of short reads (50-400 bases). 
NGS parallelization of the sequencing reactions generates hundreds of megabases to 
gigabases of nucleotide sequence reads in a single instrument run. This has enabled a drastic 
increase in available sequence data and fundamentally changed genome sequencing 
approaches in the biomedical sciences. Newly emerging NGS technologies and instruments 
have further contributed to a significant decrease in the cost of sequencing nearing the mark 
of $1000 per genome sequencing (8).  Examples of these NGS platforms are the Roche 454® 
or Illumina®. 
 
The DNA microarray (Figure 12) or biochip is a collection of microscopic DNA 
features attached to a solid support (glass, plastic or silicon). They allow the assessment of 
DNA segments that are present in a given sample. In the pharmaceutical research, the 
microarrays are used to address three basic questions: gene expression, genetic tests and 
comparative genomic hybridization.  
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Pharmacogenomic tests can use these microarrays as gene expression tools, as they 
can give insight to the underlying mechanisms of drug response, and as genetic tests, as they 
may be composed of a battery of potential SNPs.  
Array comparative genomic hybridization has, in the past few years, superseded 
traditional chromosome-based methods for the detection of genomic copy number 
variations. It permits higher resolution levels than chromosome-based methods, facilitating 
identification of chromosomal changes, such as microdeletions and duplications (9). 
  
 
 
Figure 12 - Principles of DNA microarray: the two complementary sequences of DNA will bind (hybridize) with each 
other. Thus if one half of the DNA sequence is covalently bound to a support (array) and its complement is present in a 
sample to be assayed, the two will bind to one another. Typically, the sample of DNA sequences to be assayed is labelled 
using an isotope, fluorescent dye or chemiluminescence. These arrays yield image files containing intensity values resulting 
from the hybridization of the labelled DNA to the targets on the array. (Adapted from http://www.uni-koeln.de/med-
fak/biochemie/transcriptomics/07_analysis.shtml). 
 
Real-time PCR allows the assessment of specific quantities of specific targets with 
the ability to monitor them in real time.  Through the use of DNA dyes or fluorogenic 
probes, the amount of DNA accumulating in each cycle of the PCR amplification process can 
be quantified in real time. This way researcher can estimate the initial starting concentration 
of a given target. It is a faster, less expensive and more quantitative process than microarrays. 
On the other hand, with this technic, the number of genes that can be assayed is much less 
than in microarrays.   
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3.4 Current applications 
 
As stated before, the field of PGx includes the application of genomic technologies to 
identify networks of genes that affect drug efficacy and toxicity, ascertain new therapeutic 
drug targets and optimize current pharmacotherapeutic treatments. 
  
This means that PGx has enormous potential in the different steps of drug 
development. It can (4): 
(a) Improve the discovery of targeted drugs;  
(b) Improve proof of principle for efficacy trials (and salvage drugs); 
(c) Identify optimal dosing; 
(d) Improve drug safety and understand adverse events in the development and post-approval; 
(e) Improve the identification of patients who will benefit from genetically-defined therapy, thereby 
avoiding futile therapeutic attempts. 
 
 
 
Figure 13 - The use of PGx studies in the pharmaceutical lifecycle. Throughout the life cycle of a drug PGx studies 
can be made in order to enhance each step of the way.  In orange are the different steps in drug discovery and development 
and below are depicted the uses of PGx studies in each phase.  (Adapted from Pharmacogenomics and personalized 
Medicine, 2008). 
 
 As seen in Figure 13, pharmacogenomic studies can be applied throughout the 
process of drug discovery, development and commercialization. From the research phase to 
the drug's commercialization, the need for PGx testing exists and is well accounted for.  
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Currently, there are several pharmacogenomic tests available. The United States Food 
and Drug Administration (FDA) provides a list of pharmacogenomic biomarkers depicted in 
drug labels which, if performed (some being compulsory, like for certain oncologic drugs), will 
allow a better drug dosage or avoid ADRs. In the list bellow (Table 5) it can be found 
examples of drugs with labelled PGx biomarkers, used in cardiovascular diseases:  
 
Table 5 - Table of Pharmacogenomic Biomarkers in Drug Labels of Cardiovascular Drugs (Adapted from 
http://www.fda.gov/drugs/scienceresearch/researchareas/pharmacogenetics/ucm083378.htm). 
Drug Therapeutic Area Biomarker 
Carvedilol Cardiovascular CYP2D6 
Clopidogrel Cardiovascular CYP2C19 
Isosorbide, Hydralazine Cardiovascular NAT1; NAT2 
Metoprolol Cardiovascular CYP2D6 
Propafenone Cardiovascular CYP2D6 
Propranolol Cardiovascular CYP2D6 
 
 Recently, the development of drugs that depend on the use of a genomic test to meet 
their labelled safety and efficacy claims, has become more common (in the FDA’s Table of 
Pharmacogenomic Biomarkers in Drug Labels there are circa 100 drugs listed). Such tests can 
identify appropriate subpopulations for treatment or identify populations who should not 
receive a particular treatment because of an increased risk of a serious ADR.  
 
In Portugal, the Centro de Genética Clínica (http://www.cgcgenetics.com) provides a 
cardiovascular pharmacogenomic test (among others) that allows drug dosage adjustment. 
Based on the test result a patient can be classified as poor metabolizer, extensive metabolizer 
or intermediate metabolizer and the drug dose can then be titrated or the drug can be 
replaced if it is found to be ineffective in a particular patient. This test requires information 
Guiding Hypertension Treatment with Pharmacogenomics: the Role of the Community Pharmacist 
Ana Luisa Pedro 36 
 
about the ordering physician and the signing of an informed consent which reads: “I wish to 
make the tests above indicated, and I assure that I was properly and fully informed, so I give my 
consent. I also authorize the report to be sent to my physician and my sample to be used for 
research purposes.” 
 
 
 
 
Figure 14 - Pharmacogenomic test performed by CGC (Extract from a leaflet advertising the cardiovascular 
pharmacogenomic tests performed by CGC. (Adapted from http://www.cgcgenetics.com/cgc/en/main-en.html). 
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3.5 Pharmacogenomics and the Pharmaceutical Industry 
 
The benefit of pharmacogenomic testing in a clinical setting is clear: the right drug for a 
specific disease afflicting a particular individual. But how clear are the benefits for the 
pharmaceutical industry? 
 
There are many questions regarding the implementation of PGx testing in the 
pharmaceutical industry and how it may add value to the discovery and development of 
drugs. The loss of the blockbuster at the hands of pharmacogenomics is a key factor, but 
although there are risks like the loss of patients who are at risk of ADRs and the loss of non-
responders, there are also many benefits.   
 
The pharmaceutical industry has to gain with the possibility of an earlier market 
introduction of a drug, with faster approvals, recruiting patients to treat new subtypes of a 
disease, earlier/preventive use of drugs, enhanced patient compliance, and potential higher 
pricing and reimbursement for best-in-class drugs. 
Any concerns about the limited market resulting from drug efficacy only in patient 
subgroups could be assessed by exploring a broader group of patients once ideal proof-of-
efficacy has been achieved. 
  
 The pharmaceutical industry operates in a highly regulated environment, inspected by 
health authorities such as the United States FDA and the European Medicines Agency (EMA), 
and it has obligations to its stakeholders, such as patients, physicians and stockholders. The 
introduction of PGx studies may present benefits and also risks that need to weighed.  
 
 Nevertheless, the application of PGx testing is already on the way and becoming a 
transversal issue in the all process of pharmaceutical life-cycle, as can be seen in Figure 15. 
 
 In drug discovery, pharmacogenomic testing can be found from the very start of the 
process, with the choice of the target, the choice of the chemical lead, the pre-clinical testing 
and clinical development, onto the identification of new compounds successfully transitioned 
into the clinic (4). 
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Figure 15 - Biomarkers use during drug discovery and development. The development of predictive safety and efficacy 
biomarkers are expected to reduce the time and cost of drug development. The use of biomarkers can further facilitate 
decision-making through preclinical development and into clinical trials. (Adapted from FDA Drug-diagnostic Co-
development draft concept paper – 2005).  
 
 
Specifically, in an exploratory study for target selection and toxicity prediction, PGx is 
useful for patient segmentation (drug efficacy) and can be specific for each individual (drug 
toxicity). However, in areas such as oncology, efficacy PGx can be used more specifically to 
select patients where ADRs must be avoided, in those in whom there is little chance of 
efficacy.  
Early efficacy PGx (phase I and II) can also lay the foundations for identifying patients 
who require a different drug regimen. The ability to identify subgroups of patients responding 
in a different way to compounds during phase II development could permit the progression 
of multiple compounds for the same therapeutic area with patients being stratified to the 
compound by genotype(9).  
 
 The European regulatory health authority (EMA) has recommendations on how to 
implement pharmacogenomics during the different phases of clinical development, starting 
with the in vitro studies conducted before investigation of the medicinal product in man laid 
down in its  “Guideline on the use of pharmacogenomic methodologies in the pharmacokinetic 
evaluation of medicinal products”(December 2011).  
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The pharmaceutical industry is adapting itself to this new paradigm, not only in its way 
of thinking the drug development process, but also in its infrastructures.  
The key elements to consider when establishing a pharmacogenomics infrastructure in 
a pharmaceutical industry setting are the following (4): 
 Develop stringent procedures to enable routine collection of samples in clinical trials 
and either the de-identification or anonymization of the samples for long-term storage 
to ensure the privacy and confidentiality of the subjects. Develop informed consent 
forms and pharmacogenomics protocol templates which meet high ethical and 
regulatory standards; 
 Develop laboratory capabilities, including a biobank, with stringent and standardized 
procedures and an adequate data management system to store information about 
DNA samples, genotyping and clinical data; 
 Develop bioinformatics and biostatistics capabilities to create tool to mine and 
analyse the genetic data and to generate reports; 
 Develop a pharmacogenomics strategy as a part of a clinical development  plan 
involving a multifunctional team – pharmacogenomics and discovery scientists, clinical 
pharmacologists, physicians, statistics/bioinformatics specialists, commercial/marketing 
experts, and regulatory affairs and diagnostic consultants; 
 Pharmacogenomics implementation:  
  a. collecting samples in all trials is highly recommended; 
  b. where possible, use genomics information to guide trial design; 
c. include pharmacogenomics as early as possible in the overall development 
program and examine the feasibility of linkage of the drug to a companion 
diagnostic as early as possible; 
d. where candidate gene approach is inadequate, evaluate the feasibility of a 
genome  wide screen approach; 
e. do not limit application of pharmacogenomics to biomarker identification. 
Exploit pharmacogenomics to identify or support mode of action in vivo, and 
to optimize discovery processes and clinical trials; 
f. consider both DNA and RNA markers, as well as other types of markers  
(imaging, proteomics) when appropriate; 
g. pharmacogenomics in clinical trials should be a balancing act of experiments 
where hypothesis are being generated and tested. 
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The use of pharmacogenomics in drug discovery can improve the decision-making 
process and provide substantial cost savings by reducing timelines and promoting the 
judicious allocation of resources. In drug discovery, genetic variability analysis should be 
performed as soon a prospective target is identified. Potential benefits of early analysis 
include avoiding targets with unmanageable variability, and selecting the variant(s) that are 
most prevalent in human populations, thus improving the likelihood of success in clinical 
trials. 
 
Once a compound is adequately characterized, early integration of pharmacogenomics 
biomarkers into development can ideally lead to faster development, approval, adoption and 
penetration, and will in turn lead to commercial advantages that will outweigh the 
disadvantages of smaller eligible patient populations. Additionally, earlier opportunity 
assessment can facilitate a company's potential to adequately differentiate a compound and 
strengthen its value proposition for pricing and reimbursement authorities (11). 
 
Pharmacogenomics is challenging for both pharmaceutical development and 
commercialization. It is an innovative area of knowledge that allows product differentiation, 
competitive advantages and Research & Development (R&D) productivity enhancement. The 
regulatory agencies are up-to-date with these challenging changes and so is science. The 
discovery of reliable genetic markers is also highly important, in spite of the difficulty of 
identification of valid associations with the drug response.  
 
The development of PGx science and technology, applicable to the individualised drug 
therapy is proceeding at a rapid pace, such as it not a matter of “if” it could be put to action, 
but rather “when” it will become part of a clinical routine, leading to a major impact in 
worldwide healthcare. 
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4. Pharmacogenomics and Hypertension 
 
Cardiovascular diseases are the major cause of death in the developed world. They are 
a large group of multifactorial pathologies in which hypertension is present in a large number 
of these diseases. Except for particular cases, such as existence of concomitant pathologies, 
hypertension can be treated with a variety of drugs, independently of which, as long as 
lowering blood pressure is obtained. Nevertheless, circa 15% of all patients do not respond to 
any treatment, even those that comprise the use of two or more drug combination. One of 
the reasons for this resistance is the genetic variability between individuals (1). 
 
There have been identified groups of genes that are involved in these different 
responses (1): 
1. Genes regulating the pharmacokinetics phase of the drug: Cytochromes 
P450: CYP2D6 and CYP2C9-C19 are the most frequently involved (captopril, diltiazem or 
nifedipine are some examples). However, transporters like those of the ABC family also have 
been taken into account (atenolol or losartan); 
2. Genes related to the pharmacodynamics phase: the enzymes inhibited by 
the drugs (e.g., angiotensin converting enzyme) and the receptors involved in their actions 
(beta-adrenergic receptors, angiotensin I and II receptors) are also important 
pharmacogenomic targets; 
3. Gene polymorphisms from the patients under treatment related to the 
pathology introduce a third range of pharmacological variability (e.g., inflammation pathway 
genes); 
4. Health and physiological mechanisms (e.g., age, gender, ethnicity, weight) could 
also modify the gene polymorphisms' effect; 
5. Environmentally sensitive genes are important and interfere in the 
pharmacogenomic response of many drugs. 
 
Ideally, the development of new antihypertensive drugs and the choice of the existing 
one for clinical use, should take into account these polymorphisms in order to adapt the 
drug dosage to each individual and to avoid side effects. 
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Drug’s efficacy and toxicity can be affected by both pharmacokinetic and 
pharmacodynamics related polymorphic genes. 
 
Pharmacokinetic related genes:  
  a large number of cardiovascular drugs are lipophilic, which means that the 
polymorphism in the genes related to the absorption, distribution, metabolism and 
elimination have a high impact on the response to these drugs. Phase I enzymes, such as 
those belonging to the cytochrome P450 family, are very important for the metabolizing of 
drugs. CYP2D6 is not a major CYP enzyme in terms of quantity in the liver, but it 
metabolizes one quarter of all drugs, and many of the ones used in hypertension. Poor 
metabolizers display exaggerated response and may be at greater risk for toxicity if a drug is 
principally metabolized by CYP2D6. In contrast, ultra-rapid metabolizers may not achieve 
therapeutically active plasma concentration for certain drugs. Genotyping an individual by 
Polymerase Chain Reaction (PCR) methods can be used to predict the metabolizer status, 
and specific DNA chips are now on the market, such as AmpliChip®, marketed by Roche 
Diagnostics. CYP3A enzymes metabolize circa 50% of all drugs. As such, they are often 
implicated in ADRs and drug-drug interactions; 
 Phase II enzymes, such as N-acetyltransferase 2 (NAT-2) and UDP-glucuronosyl-
transferases (UGTs), are not considered to have a great impact in the metabolizing of 
antihypertensive drugs; 
 Phase III enzymes (drug transporters), have important roles as they determine 
drug disposition, intestinal absorption and renal elimination. There are five classes of uptake 
carrier systems (organic anion transporters –OATPs; organic cation transporters – OCTs; 
dipeptide transporters – PEPTS; nucleoside transporters – CNTs; monocarboxylate 
transporters – MCTs) and the ATP-binding transporter related to the efflux of drugs and 
metabolites (ABC). Another major drug transporter across renal and intestinal cells is P-
glycoprotein (P-gp). Verapamil is an antihypertensive drug that is a substract to both CYP3A 
and P-gp. 
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Table 6 - Examples of anti-hypertensive drugs affected by polymorphisms of the CYP450 family enzymes and transporters 
Phase I enzymes and transporters implicated in anti-hypertensive drug 
metabolism (examples) 
Substrates Enzyme (CYP450 family) Transporters 
Losartan 3A, 2D9 ABCB1 
Carvedilol 3A, 2D6 ABCB1 
Verapamil 1A2, 3A, 2C8 ABCB1, OCT1 
Enalapril 3A OATP, PEPT 
Captopril 2D6 OATP, PEPT 
Diltiazem 3A, 2C9, 2D6 ABCB1 
 
Pharmacodynamic related genes:  
Equally important is the evaluation of variations in gene sequence of pharmacological 
targets. There are several pharmacological targets, including receptors, enzymes, ion channels, 
lipoproteins and signal transduction pathways. They are localized or expressed differently in 
tissues and cells. These targets exhibit genetic variability that can alter the binding affinity of a 
drug or its metabolites, and thus modulate drug response. For antihypertensive drugs, the 
main described polymorphisms influencing pharmacodynamics are: 
i. Angiotensinogen (AGT); 
ii. Angiotensin II receptor type 1 (AGTR1); 
iii. Angiotensin-converting enzyme (ACE); 
iv. α-adducin (ADD1); 
v. Bradikinin receptor B2 (BDKRB2). 
 
Table 7 - Examples of anti-hypertensive drugs affected by gene polymorphisms that influence the pharmacodinamic phase of 
drug actions 
Polymorphic genes influencing pharmacodynamics 
actions of anti-hypertensive drugs 
Gene Example Clinical consequences 
Α-adducin 
Hydrochlorothiazide 
(HCTZ) 
Greater reduction in blood pressure to HCTZ 
treatment 
ACE Enalapril Greater and longer drug response 
AGT Several drugs 
Reduction of blood pressure and decrease in left 
ventricular mass with anti-hypertensive treatment 
AGTR1 ARB 
Increase arterial responsiveness to angiotensin II 
in ischaemic heart disease and increased aortic 
stiffness in hypertension 
BDKRB2 ACEI ACEI related cough 
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 In Figure 16 is depicted the pathway of the drugs acting in the RAAS as well as the genes 
involved in the PD of the same drugs. 
 
Figure 16 - Genes involved in the pharmacodynamics of the drugs that act on the renin-angiotensin-
aldosterone system. The renin-angiotensin-aldosterone system is central to the control of blood pressure and the target 
of several types of anti-hypertensive drugs. This pathway depicts a simplified representation of the pharmacodynamics of 
RAAS-acting drugs including candidate genes for the pharmacogenomics of ACE inhibitors, angiotensin receptor blockers, 
renin inhibitor aliskiren and aldosterone receptor antagonists. The core of this pathway involves the conversion of 
angiotensinogen to angiotensin I (Ang I) by renin, its subsequent conversion to angiotensin II (Ang II) by angiotensin 
converting enzyme. Ang II activates the angiotensin II receptor type 1 to induce aldosterone synthesis, increasing water and 
salt resorption and potassium excretion in the kidney and increasing blood pressure. The key candidate genes involved in 
the core pathway are angiotensiogen, AGT; renin, REN; angiotensin converting enzyme, ACE; and angiotensin II receptor 
type 1, AGTR1. (Adapted from http://www.pharmgkb.org/pathway with permission given by PharmGKB and Stanford 
University). 
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 There is often a family history of high blood pressure in hypertensive patients, 
suggesting that inheritance contributes to the pathogenesis of this disorder. Essential 
hypertension is a highly heterogeneous disorder, which points to a multi-factorial and 
polygenic etiology. Variants in some genes might render an individual sensitive to a given 
factor in the environment. On the other hand, the patient´s genetic predisposition might 
influence drug-metabolizing enzymes and this in turn might affect both efficacy and adverse 
effects of antihypertensive therapy (2).  
 
4.1 Anti-hypertensive Drugs and Pharmacogenomic Studies 
 
Renin-Angiotensin-Aldosterone System 
 Genetic variations corresponding to this system have been shown to be associated 
with a tendency to high blood pressure: 
 ACE inhibitors: the ACE insertion/deletion polymorphism is one of the most known 
polymorphism of the RAAS which is linked to hypertension. The deletion allele of the 
polymorphism is strongly associated with an increased level of circulating ACE, which can 
alter the response to ACEI; 
 ARBs: angiotensin receptor blockers provide a complete and specific suppression of 
the RAAS. They decrease blood pressure by blocking the binding of Ang II to the angiotensin 
type I (AT1) receptor. Also, ARB administration indirectly activates the AT2 receptor by 
blocking feedback inhibition of renin release and shunting the angiotensin II generated from 
AT1 and AT2. The A1166C polymorphism of the AT1 receptor gene was studied in relation to 
the response to losartan and was found that patients with the CC genotype were less 
responsive than with the AA genotype (3). This is an example, if this marker reveals to be 
strong, where a pharmacogenomic test can be used to predict the response to losartan; 
 Renin Inhibitors: overexpression of renin predisposes individuals to develop 
hypertension. Aliskiren is presently, the only available drug that belongs to this group. 
Although there are some studies, they are not yet predictive for the use of this drug. 
 
Beta-Blockers  
Beta-blockers are widely used in hypertensive patients. Two major polymorphisms 
encoded by the beta-1 adrenergic receptor gene – ADRB1 - are commonly used in both 
hypertension and heart failure pharmacogenetics studies of beta-blockers. These 
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polymorphisms result in an amino acid substitution at codon 389 (Arg389Gly, 
C1165Gpolymorphism) that codes for the intracellular part of the receptor and at codon 49 
(Ser49Gly, A145G polymorphism) that codes for the extracellular part of the receptor.  
Based on the functional data of these SNPs, they have been extensively studied for 
associations with response to beta-blockers, with the hypotheses that the more responsive 
Ser49 and Arg389 forms would be the ones with the greatest β-blocker efficacy (4). 
 
Diuretics 
 The C825T polymorphism of the G-protein beta-3-gene (GNB3) appears to predict 
patient response to thiazide diuretics, while CA repeat length of the 11-beta- hydroxysteroid 
dehydrogenase type 2 (HSD11B2) gene has been strongly associated with the blood pressure 
response to HCTZ (1). 
 
4.2 Future directions 
Despite all the studies performed regarding this subject – Pharmacogenomics and 
Hypertension - a strong relation between genomic variance and drug response is not yet fully 
established. 
A search performed in the website of the National Centre of Biotechnology 
Investigation,  under the PubMed link 
(http://www.ncbi.nlm.nih.gov/pubmed?term=pharmacogenomics),  made in the 15th of 
December 2012, showed that there were published 1,165 papers under the search term 
“pharmacogenomics”  in the current year (321 reviews),   and 16,435 papers under the 
search term “hypertension”. When the search was performed under the search terms 
“pharmacogenomics and hypertension” only 25 were found, two of which were related to 
pulmonary hypertension.  Under the search term “pharmacogenomics and cancer”, in the 
current year, 225 papers were published. 
One of the most helpful PGx databases, as considered by the American Pharmacist 
Association, is available at http://www.pharmgkb.com. In this web site, which is presented as 
“a comprehensive resource that curates knowledge about the impact of genetic variation on 
drug response for clinicians and researchers”, a specific link can be found to well-known 
pharmacogenomic associations. Given our study subject – pharmacogenomics of 
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antihypertensive drugs – it could only be found direct therapeutic dose recommendations for 
one drug: metoprolol (a beta-blocker). 
Also, in 2011, the National Heart, Lung, and Blood Institute Working Group (USA), 
issued a report regarding cardiovascular pharmacogenomics current status and future 
directions, where three major emerging PGx applications were reviewed:  anticoagulation 
(warfarin), antiplatelet therapy (clopidogrel), and lipid-lowering therapy (statins) (5). 
Pharmacogenomic studies of anti-hypertensive drugs were not considered a “pressing clinical 
need”.  
Nevertheless “genetic determinants of blood pressure and long-term outcomes in 
hypertensive patients are being identified, and their role in choosing among therapies is under 
active investigation” (6). 
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5. Pharmacogenomics in the 
Community Pharmacy Practice 
 
The Community Pharmacy and its community pharmacists are important pillars in the 
delivery of health products to the population: drug products, technical aids, point-of-care 
tests or pharmaceutical care plans are some of the services already available at any pharmacy.  
Being able to provide PGx testing in a community pharmacy setting gives the pharmacist yet 
another opportunity to help individualize drug therapy, maximising efficacy (the right drug 
and the right dose) and minimising toxicity based on patients’ genetic data.  
Pharmacogenomic tests along with other point-of-care tests can increase access to 
information that can be used to guide and monitor drug therapy.   
 
The community pharmacy is equipped with both professionals and facilities that can 
easily integrate this practice in its many provided services and products.  
The community pharmacist has a broad knowledge in pharmacology that allows 
him/her to easily acquire the skills necessary to implement a PGx service in the community 
pharmacy practice. Nevertheless, it is compulsory that for being able to provide this service, 
the pharmacist will have to acquire deep knowledge in PGx, as it integrates not only specific 
technical aspects such as handling patient samples but also cognitive actions such as critical 
appraisal of evidence (need to be up-to date with current drug monitoring technics and 
scientific literature), decision-making, interpreting test results and providing counselling to 
patients. On the other hand, these latter activities are not strange to the pharmacist as they 
are already employed in several services provided. 
The community pharmacy has evolved in its purpose, especially in the last two decades, 
from being where the “drug specialist” works and drugs are sold, to where patients can find 
professionals that are interested in their well-being, providing services that can answer 
specific questions and helping monitor the results in each counselling. This meant some 
changes, even in the physical structure of the community pharmacy, where now it can always 
be found a place where patient and pharmacist can talk in private and where an increasing 
number of services are performed, such as vaccination, drug administration and monitoring 
analysis.  In fact, the community pharmacy is highly equipped to include PGx in its service 
portfolio.  
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5.1 Integrating PGx in the Community Pharmacy Practice 
 
A community pharmacist has to able to improve drug efficacy and safety, by having 
more knowledge of the current drug monitoring technics, pharmacogenomic tests included.  
Nowadays, pharmacovigilance plays an important part in providing information on drug 
safety, and it is common for a pharmacist to refer back to the prescribing physician any 
possible drug-drug interaction or side effect. Nevertheless, pharmacogenomic testing could 
avoid those unwanted effects.  
 
Recently, a new website was launched, in Portugal, which enables healthcare 
professionals and members of the public to report any reaction to a drug: 
http://extranet.infarmed.pt/page.seram.frontoffice.seramhomepage.   
 
 
Figure 17 - Portuguese website that enables reporting adverse drug reactions 
(http://extranet.infarmed.pt/page.seram.frontoffice.seramhomepage). 
Not long ago, reporting a side-effect of a drug was considered to be the physician´s 
chore, but as the society is becoming more active, where every part involved in one given 
medical treatment has the right and duty of alerting to the consequences of such treatment, 
good or bad. Patients and all healthcare professionals should not only be proficient in 
choosing the right drug but also in avoiding the drugs side-effects, and implementing 
pharmacogenomics in the common practice is a clear path to follow. 
 
Every health professional should be educated in genetics and pharmacogenomics 
sciences, not only those professionals who prescribe drugs, but also those who dispense and 
monitor them.  
Graduated pharmacy studies should offer courses in such a subject and a post-
graduation should be presented to those pharmacists who wish to deepen their knowledge 
in PGx.  
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Newly graduated pharmacists, although equipped with many knowledge involved in the 
understanding of PGx science, need to be in a continuous educational program to become 
proficient in this matter. This, then, must be the first step: educating community 
pharmacists in PGx. 
 
However is not only the community pharmacist that needs to be educated in PGx: 
physicians and patients also need to know about this rapidly evolving science, especially in 
what it means to be tested for specific pharmacogenomic traits and how it will be helpful 
when establishing a drug therapy.  And here, the community pharmacist may also play a 
predominant role:  the pharmacist can be the conveyer of knowledge in PGx to the physician 
and patient by facilitating the access to PGx testing and assisting in physician and patient 
education. 
 
But, being able to provide pharmacogenomics services in a community pharmacy poses 
some likely questions such as:  
 What role must the pharmacist have in providing such services?; 
• What may be the impact that these services on the practice of pharmacy?; 
• What are pharmacogenomic services, and what activities must a pharmacist 
undertake to provide those services?; 
• What is their clinical utility?; 
 Are these tests cost-effective? 
 
If there is sufficient interest and demand from patients, it is in the community pharmacy 
that these tests will have a major impact. Not only in acknowledging the possibility of taking 
these tests, but also in providing them to the patients, making sense of them and finally 
advising the patients accordingly.  
This means, of course, that pharmacists would require training in the interpretation of 
test results, as well as dealing with ethical concerns and issues of patient confidentiality. 
For a community pharmacist, it is important to know what it means to have a particular 
genomic alteration, but also to know what it implies for the patient: are there alternative 
drugs?, may the patient thrive without medication? The pharmacist has to be able to answer 
the patient’s questions about the result of the test and know where to get as much 
information as possible.  
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Also, clear recommendations must be given from the drug producer or health 
authority, on what pharmacogenomic test has to be performed, in which circumstance, for 
which patient, regarding which health condition.  As seen in Table 5, there are already drugs 
with PGx information in their labels.  Some, but not all, of the labels include specific actions 
to be taken based on genetic information. An example of a box warning present in a drug 
label is depicted in Figure 18. Biomarkers may include gene variants, functional deficiencies, 
expression changes, chromosomal abnormalities, and others.  
 
 
Figure 18 - Excerpt of the Plavix® label (box warning), where is stated that CYP2C19 weak metabolizers need to titrate 
drug dosage and information about drug-drug interaction. 
 
5.2 Proposed Action 
 
The integration of PGx in the community pharmacy seems not to be difficult to 
achieve, as it means to provide an alternative or additional test that can be performed at the 
pharmacy, by the pharmacist, and which result can also be checked and acted upon in the 
same place.  
 
Instead of doing the theoretical risk-assessment based on the current, and sometimes 
weak, knowledge of the patient health condition, the physician’s diagnostic (if known) and the 
prescription available, the pharmacist can offer the patient an additional PGx test to confirm 
the relevance of the drugs prescribed and to which extent they may be able to cause ADRs 
or interact with other drugs used by the him/her. 
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Exactly, what kind of service is involved in pharmacogenomic testing?  
Within the current pharmacy practice framework, pharmacogenomics advice can be 
given based on information from various sources and by the pharmacist at the point of 
dispensing or sale. The advisory role of the pharmacist, which includes informing patients 
about how to take their medications and how to avoid drug-drug and drug-diet interactions, 
can be expanded to include pharmacogenomics.  
As for the providing of the tests, there should be no major difference from what is 
already done when glucose, cholesterol or blood pressure measurements are made in a 
pharmacy setting.  The sample collection for a PGx test usually includes a mouth swab, a 
painless and non-invasive technic which allows the collection of cells from which is extracted 
genetic material needed to perform the test.  In a first approach, the PGx test itself will not 
be performed at the pharmacy, pharmacists will only have to collect the sample and send it 
to a referenced laboratory.  
 
Nevertheless, a pharmacist has to undertake some activities if he/she wants to offer 
pharmacogenomics services, such as being able to: 
1. Establish a professional understanding with the patient’s physician – for a PGx 
service to be successful, a trustful and professional relationship between pharmacist and 
physician must be established. Otherwise, the result of a PGx test may not lead to changes 
needed in drug therapy, as the patient may not feel safe if his/her physician does not take part 
in this decision; 
2. Critically appraise evidence – not all patients need a PGx test. It is extremely 
important for a pharmacist to be able to determine the relevance of such test in patient care; 
3. Make decisions and manage risk – once the result of a PGx is known, decisions 
have to be taken and the pharmacist has to be able to make recommendations based in those 
results, always bearing in  mind the patient’s safety; 
4. Understand one’s own limits – as a part of a team (physician-patient-
pharmacist) the pharmacist must know that every member of the team must agree on the 
action to be taken and whether this service is of not helpful for the patient; 
5. Obtain, handle and test patient samples; 
6. Solve problems and keep appropriate records – it is of extreme importance to 
keep recorded all facts and figures involved in a given PGx test for every particular patient. 
This will back up actions taken and permit following reviews, if needed; 
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7. Develop diagnostic and disease monitoring skills, synthesize patient data and 
genetic data; 
8. Communicate effectively and provide relevant counselling to both patient and 
physician -  what is the value of testing, what does each result mean, what can be done upon 
getting the result, what’s expected to happen after any action is taken; 
9. Obtain informed consent – compulsory. 
 
In Figure 19 is depicted a flowchart that illustrates the actions that can be taken when 
performing a PGx test in a community pharmacy. When filling a prescription or when asked 
by a patient, a PGx educated pharmacist should be able to identify any PGx relevance related 
to the drug(s) prescribed. If there is a PGx test available and it is found suitable and feasible 
for a particular patient, then information about it, such as how it works, what means to take a 
PGx test and what can be done upon getting the result, must be clearly presented to the 
patient. Once the patient decides to take the test, the physician must be informed, not only 
that there is a PGx available for his/her patient but also about the willingness of the patient 
to be tested. Before samples are collected an Informed Consent must be signed.  
The sample collection is done, for most of the tests available, by a mouth swab, which is 
considered a non-invasive and a rapid bio-sample collection method. It is very easy to 
perform, with virtually no restrain. After the sample is collected it must be sent to a 
referenced laboratory where the PGx study will be performed. The pharmacist should then 
receive the results and its report as soon as possible.  
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Time is of essence when a therapy must be initiated as soon as possible or a change in 
therapy may bring major benefits for a given patient. Ideally, the exchange of information 
between pharmacist-lab-physician-patient should have little interference and it should be 
done effectively and rapidly. It will be most helpful to create a web based information system 
which enables this exchange of information to be clear, specific, patient and result oriented, 
that allows the recording of all results and actions taken, that can be a useful guide to the 
patient, but also easy to consult by the parties involved, and that makes it possible to look 
back on actions taken and better interpret what is involved in this kind of study.  A PGx 
testing data flow diagram, which can be built as a web based platform, is proposed in Figure 
20. 
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Figure 20 - Pharmacogenomic Testing Data Flow Diagram. Blue boxes indicate actions that can be performed in a 
web based information system, red boxes indicate actions performed by the indicated intervenient, which can be recorded in 
the information system but are performed outside, and the orange box indicates an activity that is performed only by the 
pharmacist, inside the information system, and that can report back to the patient and physician. 
In this valuable exchange of information between pharmacist, laboratory, physician and 
patient, where no data must be lost or undervalued, it is highly important to count on a 
reliable information system. The development of an information system should be coded as a 
web based platform easily available to every part involved in a PGx assessment. Nevertheless, 
if or when this platform is not available, the use of other means of communication such as 
fax, telephone, mail or even face-to-face consultations may be performed.  
When a pharmacist receives the report of a PGx test he/she must build a 
recommendation based on the results with the help of algorithms and on up-to-date 
scientific literature. Only then must the pharmacist send the results and report of the PGx 
test, along with the recommended actions to the physician.  The physician must, then, validate 
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the proposed recommendation, whether accepting or rejecting it, or even adding its own 
recommendation. Finally, the patient must be informed.  
But the role of the pharmacist must not end here. The monitoring of the results of the 
actions taken (suspend, switch or titrate medication) can and must be performed by the 
community pharmacist. 
 
As was stated before, for anti-hypertensive drugs, there are few labelled 
recommendations, and of the ones presented none is stringent to the performance of a PGx 
test. Nevertheless, as this is a therapeutic class of drugs that is prescribed based a trial-and-
error practice, the use of these tests may be of great help in the near future.  Also, it is a 
novel opportunity for community pharmacist to gain greater recognition as members of the 
primary health care team.  
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6. Conclusion 
Pharmacogenomics is a new science with many obstacles yet to overcome. Lack of 
comparative and cost-effectiveness data (no clinical trials or studies were found that 
reflected cost-effectiveness data of a PGx test, although it is commonly stated that it may 
bring savings to both patient and reimbursement system) and the need for education and 
clinical practice guidelines are probably the most pungent issues to assess. In the specific case 
of PGx in hypertension treatment, the search of solid biomarkers that can help make a 
decision for treatment is far from being completed. But, it is believed that the 
implementation of the PGx testing should be at pace with science and not be far behind. 
Although PGx testing is taking its first steps, several healthcare communities are starting to 
implement these tests: in Australia, there are already timelines for the implementation of PGx 
in the community pharmacies, being the short-term implementations set prior to 30 June 
2015, medium-term between 30 June 2015 and 30 June 2020, and longer-term after 1 July 
2020 (1).  
 
Applying PGx tests to patients under anti-hypertensive treatment is a challenge. 
Recently, in November 2012, the Jornal de Notícias, reported that, according to the Infarmed 
(Portuguese Health Authority), the Portuguese public health system spent over one million 
euros per day in cardiovascular drugs reimbursement (Figure 21).  
Figure 21 - Excerpt of Jornal de Notícias, 09 November 2012 (on the left):  “The SNS (Portuguese public health system) 
spent, last year, over a million euros per day in the reimbursement of cardiovascular drugs according to a study performed 
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by Infarmed, which confirms a significant raise in the use of these drugs. According to this study, cardiovascular drugs 
account for 30% of total SNS expenditure in ambulatory”. On the right side of the figure is a chart, published in the 
Infarmed periodic publication – Infarmed Notícias – in November 2012, which shows the evolution of the use of 
cardiovascular drugs over the last decade. The dark yellow line represents the anti-hypertensive drugs, which account for the 
most used drugs in the treatment of cardiovascular diseases. The article news from Jornal de Notícias was written based on 
this article of Infarmed Notícias. (Available from: 
http://www.infarmed.pt/portal/page/portal/INFARMED/PUBLICACOES/INFARMED_NOTICIAS/infarmed%20not%EDcias%2
0-%20N.%BA%2044%20-novembro%202012%20-%20internet.pdf). 
 
These numbers clearly show how much the cardiovascular drugs weight in the public 
expenditure. On the other hand, they do not reflect the money spent with ADRs, drug-drug 
interactions or redundant pharmacotherapy that may occur. This can mean that PGx tests, 
although they may not be inexpensive (at least not until they are routinely used), can help 
bring these numbers down, for the benefit of patients and health systems. With so much 
money spent in the treatment of hypertensive patients, the investments made to better guide 
drug treatment should not be underestimated. 
 
Pharmacogenomics has the potential to substantially change health practice and the 
expectation of stakeholders such as health professionals and governments, and reinforce the 
position of the community pharmacist as a healthcare professional. Over the last five years, 
especially since the price of drugs plummeted, much due to the implementation of generic 
drugs in Portugal, and due to the world economic crisis, the community pharmacy has met 
serious financial difficulties. In July 2012, a study performed by Nova School of Business & 
Economics, showed that more than 1100 pharmacies, out of a total of 2900, were in an 
“unbearable situation” (2). The implementation of PGx testing could also help the community 
pharmacists to find new fields of actions to better thrive.  
 
The implementation of PGx testing is not only concern of the pharmacist, patient and 
physician. Other parties, such as consumer organizations, disease management organizations, 
government and regulatory bodies, pathology organizations, pharmacy organizations, 
pharmacy software developers/vendors, product manufacturers, insurance companies, 
reimbursement system and any health professional bodies can and will take active part in the 
development and implementation of these tests. It is high time to incorporate PGx testing 
into the everyday practice in clinical and pharmacy settings. 
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